• Moesin as a Biomarker of Endothelial Injury Severity in Seps

  2026-04-22

  This study identifies moesin (MSN) as a novel biomarker strongly associated with endothelial injury in sepsis, linking MSN levels to disease severity and vascular dysfunction. The paper provides mechanistic insights into how MSN modulates endothelial permeability via Rock1/MLC and NF-κB signaling, with implications for both diagnosis and research model development.

• NF 340: Potent P2Y11 Antagonist for Targeted GPCR Modulation

  2026-04-22

  NF 340 is a selective P2Y11 antagonist that inhibits purinergic receptor signaling, enabling precise modulation of GPCR pathways in immunology and inflammation research. Its utility is validated in mechanistic studies of cancer cell invasiveness and immune function.

• Mtb Exploits BMX Kinase to Block Lysosomal Acidification in

  2026-04-21

  This study uncovers how Mycobacterium tuberculosis (Mtb) enhances its intracellular survival by promoting BMX kinase-dependent phosphorylation of the host ATP6V1E1 subunit, disrupting lysosomal acidification. The discovery identifies a host-pathogen signaling axis that could be therapeutically targeted to improve clearance of Mtb.

• Palbociclib (PD0332991): Applied Workflows in Cancer Models

  2026-04-21

  Palbociclib (PD0332991) Isethionate offers precise, reproducible control over cell cycle arrest and apoptosis in advanced cancer models, including complex assembloids. Discover protocol enhancements, troubleshooting strategies, and insights that translate this CDK4/6 inhibitor’s selectivity into robust, publication-ready data for breast cancer and renal cell carcinoma research.

• Isradipine (Dynacirc): Reliable L-Type Ca Channel Blockade i

  2026-04-20

  This article addresses key laboratory challenges in cell viability, neuroprotection, and hypertension research, providing scenario-driven solutions with Isradipine (Dynacirc), SKU A8453. Drawing on high-purity product data and current literature, we clarify evidence-based best practices, protocol parameters, and vendor selection strategies to enhance experimental reproducibility and workflow confidence.

• Phenytoin (SKU B2271): Advancing Sodium Channel Modulation R

  2026-04-20

  This article offers scenario-driven guidance for leveraging Phenytoin (SKU B2271) in sodium channel modulation and cell-based assays. It addresses common challenges in assay reproducibility, compound handling, and data interpretation, with evidence-based strategies for improved workflow reliability. Phenytoin’s properties, purity, and vendor selection are critically analyzed for biomedical researchers.

• Pazopanib Hydrochloride in Cancer Research: Optimized Workfl

  2026-04-19

  Pazopanib Hydrochloride (GW786034) empowers cancer researchers to dissect angiogenesis and tumor proliferation using data-driven, multi-targeted inhibition. This guide distills advanced in vitro protocols, troubleshooting strategies, and actionable insights from systems biology to unlock reproducible results in renal cell carcinoma and soft tissue sarcoma studies.

• CUL3-KEAP1 Complex Controls PHD2 Ubiquitination and Degradat

  2026-04-18

  This study reveals that the CUL3-KEAP1 E3 ubiquitin ligase is essential for mediating the ubiquitination and degradation of PHD2, a central enzyme in the hypoxic response. By integrating label-free interactome analysis and functional validation, the authors clarify a previously underexplored mechanism regulating PHD2 homeostasis, with implications for hypoxia-driven tumor biology and protein tagging workflows.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Tracking & Ass

  2026-04-17

  EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) bridges real-time mRNA tracking with robust protein expression, leveraging both Cy5 fluorescence and bioluminescence readouts. Explore optimized workflows, evidence-backed protocol parameters, and actionable troubleshooting tips for advanced translational research.

• ATM-Targeted TACE Silencing: Alleviating Obesity-Induced Dia

  2026-04-16

  This study introduces a non-viral oligopeptide system (ATS-9R) for targeted gene silencing in visceral adipose tissue macrophages, focusing on TACE knockdown to reduce inflammation and improve insulin sensitivity in obesity-induced type 2 diabetes. The findings establish a mechanistically precise strategy for metabolic disease intervention via Prohibitin-mediated endocytosis.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Lab G

  2026-04-15

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) prevents unwanted protein degradation during extraction and analysis by inhibiting multiple classes of cellular proteases. It is intended for workflows that require preservation of divalent cations, such as phosphorylation studies and enzyme assays, and should not be used where EDTA is essential or DMSO is incompatible.

• Cyclic Pifithrin-α Hydrobromide: Precision p53 Inhibition in

  2026-04-14

  Cyclic Pifithrin-α hydrobromide is a validated p53 inhibitor widely used to dissect p53-mediated apoptosis and DNA damage responses. Its selectivity allows differentiation between p53-dependent and -independent cellular processes, streamlining cancer and neuroinflammation studies. This article reviews its mechanism, benchmarks, and workflow integration for research use.

• MDL 28170: Calpain Inhibitor Strategies for Neuroprotection

  2026-04-13

  MDL 28170 stands out as a selective, cell-permeable calpain inhibitor, enabling robust neuroprotection and assay specificity across neurological, cardiac, and infectious disease models. This article translates the latest mechanistic and workflow insights into actionable protocols, troubleshooting tips, and advanced applications for translational research.

• HyperScript RT SuperMix for qPCR: Accelerating Reliable cDNA

  2026-04-13

  HyperScript RT SuperMix for qPCR transforms two-step qRT-PCR, enabling reproducible gene expression analysis from low-concentration or structurally complex RNA. Its advanced enzyme and primer blend unlock high-fidelity cDNA synthesis, supporting breakthrough workflows in cancer biomarker discovery and challenging tissue assays.

• Adefovir in HBV Research: Applied Workflows and Assay Advanc

  2026-04-12

  Adefovir (GS-0393) stands out as a high-confidence probe and antiviral in hepatitis B virus research, combining potent DNA polymerase inhibition with selective OAT1 transport phenotyping. This guide translates the latest pharmacokinetic breakthroughs into robust lab protocols, troubleshooting strategies, and workflow optimizations for reproducible results.

15746 records 1/1050 page Next 12345 下5页 Last page